{
    "clinical_study": {
        "@rank": "154589", 
        "arm_group": {
            "arm_group_label": "PCI-32765", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive PCI-32765 420 mg (3 x 140-mg capsules) orally once daily."
        }, 
        "brief_summary": {
            "textblock": "An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase\n      Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic\n      Leukemia or Small Lymphocytic Lymphoma with 17p Deletion"
        }, 
        "brief_title": "A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia With 17p Deletion", 
            "Small Lymphocytic Lymphoma With 17p Deletion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, international, open-label, single arm, Phase 2 study designed to\n      evaluate the efficacy and safety of PCI-32765 in subjects with relapsed/refractory CLL or\n      SLL with del 17p. All subjects will receive PCI-32765 until disease progression or\n      unacceptable toxicity occurs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Documentation of del (17p13.1)\n\n          -  Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of\n             systemic therapy.\n\n          -  Measurable nodal disease by computed tomography (CT)\n\n        Key Exclusion Criteria:\n\n          -  History or current evidence of Richter's transformation or prolymphocytic leukemia\n\n          -  Prior hematologic stem cell transplantation <6 months from study enrollment or any\n             ongoing GVHD\n\n          -  Prior exposure to PCI-32765"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "111", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744691", 
            "org_study_id": "PCYC-1117-CA", 
            "secondary_id": "2012-004476-19"
        }, 
        "intervention": {
            "arm_group_label": "PCI-32765", 
            "description": "All subjects will receive PCI-32765 420 mg (3 x 140-mg capsules) orally once daily.", 
            "intervention_name": "PCI-32765", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CLL", 
            "SLL"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "link": {
            "description": "www.pharmacyclics.com", 
            "url": "http://www.pharmacyclics.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE\u2122-17)", 
        "other_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "18 months after last patient enrolled"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "18 months after last patient enrolled"
            }
        ], 
        "overall_official": {
            "affiliation": "Pharmacyclics", 
            "last_name": "Alvina Chu, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Health Canada", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "New Zealand: Ministry of Health", 
                "Turkey:  Clinical Drug Research Department (Klinik Ila\u00e7 Arsatirmalari Sube Mudurlugu) (MHDP)", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "6 -12  months after last patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744691"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "18 months after last patient enrolled"
            }, 
            {
                "measure": "Safety Parameters: Number and type of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months after last patient enrolled"
            }
        ], 
        "source": "Pharmacyclics", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacyclics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}